{'fraction_non_alphanumeric': 0.0295159386068477, 'fraction_numerical': 0.031877213695395513, 'mean_word_length': 4.971830985915493, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hydroxyethyl starch effects on tissue perfusion and oxygenation in patients undergoing liver surgery.

In their recent report on the results of a clinical trial on effects of hydroxyethyl starch (HES) 130/0.4 and HES 200/0.5 on microcirculation perfusion and tissue oxygenation in patients undergoing liver surgery, Cui and co-workers [1] concluded that for patients undergoing major abdominal surgeries that entail a large amount of blood loss, using HES 130/0.4 for volume replacement treatment may have potential benefit in internal organ perfusion. In support of this conclusion, two studies from Boldt and co-workers have been cited (reference 3 and 4; reference 3 is cited a second time as reference 16) which have been retracted in 2011 because of scientific fraud [2,3]. These citations and the misleading referencing need to be corrected.